Meeting
2022 ASCO Annual Meeting
Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).
Presenter
Mark R. Middleton, PhD, FRCP
University of Oxford
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Clinical Science Symposium
Session Title
Bispecifics: Are Two Better Than One?
Track
Special Sessions
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02535078
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 104)
DOI
10.1200/JCO.2022.40.16_suppl.104
Abstract #
104
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2016 Gastrointestinal Cancers Symposium
Chair
Videos & Slides
2024 ASCO Annual Meeting
T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC).
Speaker: Robin Kate Kelley, MD
Videos & Slides
2023 ASCO Annual Meeting
APP Insights: Onboarding, Scope of Practice, and Maximizing Practice
Speaker: Todd Alan Pickard, FASCO
Videos & Slides
2016 ASCO Annual Meeting
Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.
Speaker: Keith Flaherty, MD